Drug Profile
Research programme: leishmaniasis vaccine - AmVac
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator AmVac
- Class Leishmaniasis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leishmaniasis